Health Catalyst (HCAT) Stock Forecast, Price Target & Predictions
HCAT Stock Forecast
Health Catalyst stock forecast is as follows: an average price target of $29.25 (represents a 280.86% upside from HCAT’s last price of $7.68) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
HCAT Price Target
The average price target for Health Catalyst (HCAT) is $29.25 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $7.00. This represents a potential 280.86% upside from HCAT's last price of $7.68.
HCAT Analyst Ratings
According to 16 Wall Street analysts, Health Catalyst's rating consensus is 'Buy'. The analyst rating breakdown for HCAT stock is 0 'Strong Buy' (0.00%), 11 'Buy' (68.75%), 5 'Hold' (31.25%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Health Catalyst Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | Richard Close | Canaccord Genuity | $11.00 | $7.29 | 50.89% | 43.23% |
| Aug 26, 2024 | Jessica Tassan | Piper Sandler | $11.00 | $7.19 | 52.99% | 43.23% |
| Aug 08, 2024 | Jeff Garro | Stephens | $7.00 | $5.48 | 27.74% | -8.85% |
| Jun 06, 2024 | Jessica Tassan | Piper Sandler | $14.00 | $6.70 | 108.96% | 82.29% |
| Jan 26, 2024 | Jack Wallace | Guggenheim | $14.00 | $9.94 | 40.85% | 82.29% |
| May 11, 2022 | Jessica Tassan | Piper Sandler | $21.00 | $12.95 | 62.16% | 173.44% |
| Mar 02, 2022 | Elizabeth Anderson CFA | Evercore ISI | $48.00 | $27.54 | 74.29% | 525.00% |
| Mar 02, 2022 | Sean Dodge | RBC Capital | $35.00 | $27.54 | 27.09% | 355.73% |
| Feb 11, 2022 | Cindy Motz CFA | Goldman Sachs | $48.00 | $30.14 | 59.26% | 525.00% |
| May 27, 2021 | Sandy Draper | Guggenheim | $60.00 | $54.25 | 10.60% | 681.25% |
The latest Health Catalyst stock forecast, released on Sep 03, 2024 by Richard Close from Canaccord Genuity, set a price target of $11.00, which represents a 50.89% increase from the stock price at the time of the forecast ($7.29), and a 43.23% increase from HCAT last price ($7.68).
Health Catalyst Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 5 |
| Avg Price Target | - | $9.67 | $11.40 |
| Last Closing Price | $7.68 | $7.68 | $7.68 |
| Upside/Downside | -100.00% | 25.91% | 48.44% |
In the current month, the average price target of Health Catalyst stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Health Catalyst's last price of $7.68. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 08, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Sep 20, 2024 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Sep 20, 2024 | Raymond James | Underperform | Underperform | Hold |
| Sep 03, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Aug 26, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 09, 2024 | Stephens | Buy | Buy | Hold |
| Aug 09, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Aug 08, 2024 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Jul 09, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jul 09, 2024 | Piper Sandler | Underperform | Underperform | Hold |
Health Catalyst's last stock rating was published by Evercore ISI on Oct 08, 2024. The company gave HCAT a "Outperform" rating, the same as its previous rate.
Health Catalyst Financial Forecast
Health Catalyst Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $73.77M | $73.21M | $73.87M | $69.16M | $68.35M | $70.63M | $68.09M | $64.72M | $61.74M | $59.63M | $55.85M | $53.28M | $47.19M | $43.26M | $45.12M | $43.50M | $39.42M |
| Avg Forecast | $100.44M | $95.03M | $93.91M | $91.86M | $89.54M | $84.98M | $84.45M | $82.80M | $80.68M | $76.27M | $74.96M | $74.82M | $73.57M | $73.04M | $72.64M | $71.24M | $68.26M | $66.82M | $69.88M | $66.01M | $63.12M | $60.81M | $56.60M | $54.30M | $52.04M | $44.60M | $42.29M | $43.47M | $41.76M | $37.74M |
| High Forecast | $100.44M | $95.03M | $93.91M | $91.86M | $89.54M | $84.98M | $84.45M | $82.80M | $80.68M | $76.79M | $74.96M | $74.82M | $74.50M | $73.89M | $72.64M | $71.24M | $68.26M | $66.82M | $69.88M | $66.01M | $63.12M | $60.81M | $56.60M | $54.30M | $52.04M | $44.60M | $42.29M | $43.47M | $41.76M | $37.74M |
| Low Forecast | $100.44M | $95.03M | $93.91M | $91.86M | $89.54M | $84.98M | $84.45M | $82.80M | $80.68M | $76.07M | $74.96M | $74.82M | $72.88M | $72.01M | $72.64M | $71.24M | $68.26M | $66.82M | $69.88M | $66.01M | $63.12M | $60.81M | $56.60M | $54.30M | $52.04M | $44.60M | $42.29M | $43.47M | $41.76M | $37.74M |
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.01% | 1.04% | 1.01% | 1.02% | 1.01% | 1.03% | 1.03% | 1.02% | 1.05% | 1.03% | 1.02% | 1.06% | 1.02% | 1.04% | 1.04% | 1.04% |
Health Catalyst's average Quarter revenue forecast for Dec 23 based on 6 analysts is $73.57M, with a low forecast of $72.88M, and a high forecast of $74.50M. HCAT's average Quarter revenue forecast represents a -0.27% decrease compared to the company's last Quarter revenue of $73.77M (Sep 23).
Health Catalyst EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-14.39M | $-19.70M | $-23.92M | $-25.08M | $-33.35M | $-19.95M | $-12.55M | $-42.59M | $-31.56M | $-23.72M | $-16.32M | $9.81M | $-18.12M | $-20.38M | $-14.24M | $-10.16M | $-17.43M |
| Avg Forecast | $-32.38M | $-30.64M | $-30.28M | $-29.62M | $-28.87M | $-27.40M | $-27.23M | $-26.70M | $-26.01M | $-24.59M | $-24.17M | $-19.89M | $-23.72M | $-23.55M | $-23.42M | $-18.08M | $12.49M | $-21.54M | $-22.53M | $-16.44M | $-20.35M | $-19.61M | $-18.25M | $-23.51M | $-16.78M | $-14.38M | $-13.64M | $-19.37M | $-13.46M | $-12.17M |
| High Forecast | $-32.38M | $-30.64M | $-30.28M | $-29.62M | $-28.87M | $-27.40M | $-27.23M | $-26.70M | $-26.01M | $-24.53M | $-24.17M | $-15.91M | $-23.50M | $-23.22M | $-23.42M | $-14.46M | $14.99M | $-21.54M | $-22.53M | $-13.15M | $-20.35M | $-19.61M | $-18.25M | $-18.81M | $-16.78M | $-14.38M | $-13.64M | $-15.50M | $-13.46M | $-12.17M |
| Low Forecast | $-32.38M | $-30.64M | $-30.28M | $-29.62M | $-28.87M | $-27.40M | $-27.23M | $-26.70M | $-26.01M | $-24.76M | $-24.17M | $-23.86M | $-24.02M | $-23.82M | $-23.42M | $-21.70M | $9.99M | $-21.54M | $-22.53M | $-19.72M | $-20.35M | $-19.61M | $-18.25M | $-28.21M | $-16.78M | $-14.38M | $-13.64M | $-23.25M | $-13.46M | $-12.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.61% | 0.84% | 1.32% | -2.01% | 1.55% | 0.89% | 0.76% | 2.09% | 1.61% | 1.30% | 0.69% | -0.58% | 1.26% | 1.49% | 0.74% | 0.76% | 1.43% |
13 analysts predict HCAT's average Quarter EBITDA for Mar 21 to be $-23.51M, with a high of $-18.81M and a low of $-28.21M. This is -339.73% lower than Health Catalyst's previous annual EBITDA (Dec 20) of $9.81M.
Health Catalyst Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-22.03M | $-32.61M | $-33.19M | $-35.78M | $-45.73M | $-33.43M | $-22.46M | $-48.99M | $-40.01M | $-35.83M | $-28.37M | $-43.02K | $-27.33M | $-27.18M | $-17.49M | $-14.27M | $-21.42M |
| Avg Forecast | $11.58M | $10.83M | $9.78M | $7.52M | $8.61M | $7.64M | $7.88M | $6.75M | $5.54M | $5.72M | $4.75M | $-35.57M | $695.40K | $-164.86K | $-637.58K | $-32.34M | $-54.79K | $-11.25M | $-5.66M | $-29.40M | $-12.56M | $-12.89M | $-8.12M | $-40.85M | $-11.75M | $-15.83M | $-14.02M | $-23.79M | $-17.20M | $-21.60M |
| High Forecast | $11.58M | $10.83M | $9.78M | $7.52M | $8.61M | $7.64M | $7.88M | $6.75M | $5.54M | $8.57M | $4.75M | $-28.46M | $7.65M | $412.16K | $-637.58K | $-25.87M | $-43.83K | $-11.25M | $-5.66M | $-23.52M | $-12.56M | $-12.89M | $-8.12M | $-32.68M | $-11.75M | $-15.83M | $-14.02M | $-19.03M | $-17.20M | $-21.60M |
| Low Forecast | $11.58M | $10.83M | $9.78M | $7.52M | $8.61M | $7.64M | $7.88M | $6.75M | $5.54M | $2.86M | $4.75M | $-42.69M | $-1.39M | $-1.07M | $-637.58K | $-38.81M | $-65.75K | $-11.25M | $-5.66M | $-35.28M | $-12.56M | $-12.89M | $-8.12M | $-49.02M | $-11.75M | $-15.83M | $-14.02M | $-28.54M | $-17.20M | $-21.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 133.64% | 51.15% | 1.03% | 653.08% | 4.07% | 5.91% | 0.76% | 3.90% | 3.10% | 4.42% | 0.69% | 0.00% | 1.73% | 1.94% | 0.74% | 0.83% | 0.99% |
Health Catalyst's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HCAT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Health Catalyst SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $28.71M | $40.07M | $42.40M | $36.52M | $44.59M | $38.46M | $29.64M | $47.20M | $43.86M | $39.23M | $30.67M | $42.92M | $27.93M | $20.61M | $23.19M | $20.09M | $25.73M |
| Avg Forecast | $54.11M | $51.20M | $50.59M | $49.49M | $48.24M | $45.78M | $45.49M | $44.61M | $43.47M | $41.09M | $40.39M | $46.95M | $39.64M | $39.35M | $39.13M | $42.68M | $54.67M | $36.00M | $37.65M | $38.80M | $34.01M | $32.76M | $30.49M | $44.16M | $28.03M | $24.03M | $22.78M | $31.54M | $22.50M | $20.33M |
| High Forecast | $54.11M | $51.20M | $50.59M | $49.49M | $48.24M | $45.78M | $45.49M | $44.61M | $43.47M | $41.37M | $40.39M | $56.34M | $40.14M | $39.81M | $39.13M | $51.22M | $65.60M | $36.00M | $37.65M | $46.56M | $34.01M | $32.76M | $30.49M | $52.99M | $28.03M | $24.03M | $22.78M | $37.84M | $22.50M | $20.33M |
| Low Forecast | $54.11M | $51.20M | $50.59M | $49.49M | $48.24M | $45.78M | $45.49M | $44.61M | $43.47M | $40.98M | $40.39M | $37.56M | $39.26M | $38.79M | $39.13M | $34.15M | $43.74M | $36.00M | $37.65M | $31.04M | $34.01M | $32.76M | $30.49M | $35.33M | $28.03M | $24.03M | $22.78M | $25.23M | $22.50M | $20.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 1.02% | 0.99% | 0.67% | 1.24% | 1.02% | 0.76% | 1.39% | 1.34% | 1.29% | 0.69% | 1.53% | 1.16% | 0.90% | 0.74% | 0.89% | 1.27% |
Health Catalyst's average Quarter SG&A projection for Dec 23 is $39.64M, based on 6 Wall Street analysts, with a range of $39.26M to $40.14M. The forecast indicates a 38.06% rise compared to HCAT last annual SG&A of $28.71M (Sep 23).
Health Catalyst EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.39 | $-0.58 | $-0.60 | $-0.66 | $-0.84 | $-0.62 | $-0.42 | $-0.94 | $-0.82 | $-0.80 | $-0.65 | $-0.00 | $-0.68 | $-0.71 | $-0.47 | $-0.39 | $-0.76 |
| Avg Forecast | $0.20 | $0.18 | $0.16 | $0.13 | $0.15 | $0.13 | $0.13 | $0.11 | $0.09 | $0.10 | $0.08 | $0.03 | $0.01 | $-0.00 | $-0.01 | $-0.04 | $-0.11 | $-0.19 | $-0.10 | $-0.11 | $-0.21 | $-0.22 | $-0.14 | $-0.17 | $-0.20 | $-0.27 | $-0.24 | $-0.25 | $-0.29 | $-0.36 |
| High Forecast | $0.20 | $0.18 | $0.16 | $0.13 | $0.15 | $0.13 | $0.13 | $0.11 | $0.09 | $0.14 | $0.08 | $0.03 | $0.13 | $0.01 | $-0.01 | $-0.04 | $-0.11 | $-0.19 | $-0.10 | $-0.11 | $-0.21 | $-0.22 | $-0.14 | $-0.17 | $-0.20 | $-0.27 | $-0.24 | $-0.25 | $-0.29 | $-0.36 |
| Low Forecast | $0.20 | $0.18 | $0.16 | $0.13 | $0.15 | $0.13 | $0.13 | $0.11 | $0.09 | $0.05 | $0.08 | $0.03 | $-0.02 | $-0.02 | $-0.01 | $-0.04 | $-0.11 | $-0.19 | $-0.10 | $-0.11 | $-0.21 | $-0.22 | $-0.14 | $-0.17 | $-0.20 | $-0.27 | $-0.24 | $-0.25 | $-0.29 | $-0.36 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 140.29% | 53.95% | 16.31% | 5.89% | 4.43% | 6.50% | 3.92% | 4.44% | 3.77% | 5.85% | 3.82% | 0.01% | 2.55% | 3.00% | 1.86% | 1.34% | 2.08% |
According to undefined Wall Street analysts, Health Catalyst's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HCAT previous annual EPS of $NaN (undefined).
Health Catalyst Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HCAT | Health Catalyst | $7.68 | $29.25 | 280.86% | Buy |
| DH | Definitive Healthcare | $4.08 | $9.50 | 132.84% | Hold |
| FORA | Forian | $2.07 | $4.50 | 117.39% | Buy |
| SLP | Simulations Plus | $27.49 | $56.00 | 103.71% | Buy |
| CERT | Certara | $10.25 | $20.60 | 100.98% | Buy |
| EVH | Evolent Health | $23.36 | $43.00 | 84.08% | Buy |
| PRVA | Privia Health Group | $19.22 | $33.82 | 75.96% | Buy |
| PINC | Premier | $20.01 | $33.25 | 66.17% | Hold |
| HQY | HealthEquity | $86.95 | $97.00 | 11.56% | Buy |
| HSTM | HealthStream | $29.17 | $29.00 | -0.58% | Buy |
HCAT Forecast FAQ
Is Health Catalyst a good buy?
Yes, according to 16 Wall Street analysts, Health Catalyst (HCAT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 68.75% of HCAT's total ratings.
What is HCAT's price target?
Health Catalyst (HCAT) average price target is $29.25 with a range of $7 to $60, implying a 280.86% from its last price of $7.68. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Health Catalyst stock go up soon?
According to Wall Street analysts' prediction for HCAT stock, the company can go up by 280.86% (from the last price of $7.68 to the average price target of $29.25), up by 681.25% based on the highest stock price target, and down by -8.85% based on the lowest stock price target.
Can Health Catalyst stock reach $12?
HCAT's average twelve months analyst stock price target of $29.25 supports the claim that Health Catalyst can reach $12 in the near future.
What are Health Catalyst's analysts' financial forecasts?
Health Catalyst's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $341.76M (high $341.76M, low $341.76M), average EBITDA is $-110M (high $-110M, low $-110M), average net income is $30.88M (high $30.88M, low $30.88M), average SG&A $184.12M (high $184.12M, low $184.12M), and average EPS is $0.521 (high $0.521, low $0.521). HCAT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $381.24M (high $381.24M, low $381.24M), average EBITDA is $-123M (high $-123M, low $-123M), average net income is $39.71M (high $39.71M, low $39.71M), average SG&A $205.39M (high $205.39M, low $205.39M), and average EPS is $0.67 (high $0.67, low $0.67).
Did the HCAT's actual financial results beat the analysts' financial forecasts?
Based on Health Catalyst's last annual report (Dec 2022), the company's revenue was $276.24M, beating the average analysts forecast of $270.96M by 1.95%. Apple's EBITDA was $-91.708M, beating the average prediction of $-48.02M by 90.98%. The company's net income was $-137M, beating the average estimation of $-46.356M by 196.41%. Apple's SG&A was $149.22M, missing the average forecast of $167.11M by -10.71%. Lastly, the company's EPS was $-2.56, beating the average prediction of $-0.504 by 407.85%. In terms of the last quarterly report (Sep 2023), Health Catalyst's revenue was $73.77M, beating the average analysts' forecast of $73.04M by 1.00%. The company's EBITDA was $-14.39M, missing the average prediction of $-23.552M by -38.90%. Health Catalyst's net income was $-22.032M, beating the average estimation of $-165K by 13263.74%. The company's SG&A was $28.71M, missing the average forecast of $39.35M by -27.04%. Lastly, the company's EPS was $-0.39, beating the average prediction of $-0.00278 by 13928.78%